Cannabitriol

Cannabitriol
Clinical data
Other names	(+)-CBT, (S,S)-9,10-Dihydroxy-Δ6a(10a)-THC
Identifiers
	IUPAC name (9S,10S)-6,6,9-trimethyl-3-pentyl-8,10-dihydro-7H-benzo[c]chromene-1,9,10-triol;
CAS Number	74184-29-5 ; 11003-36-4 (racemic);
PubChem CID	156460;
ChemSpider	137777;
UNII	FV3E92D97V;
CompTox Dashboard (EPA)	DTXSID80911448 ;
Chemical and physical data
Formula	C21H30O4
Molar mass	346.467 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCCCCC1=CC(=C2C(=C1)OC(C3=C2[C@@H]([C@@](CC3)(C)O)O)(C)C)O;
	InChI InChI=1S/C21H30O4/c1-5-6-7-8-13-11-15(22)18-16(12-13)25-20(2,3)14-9-10-21(4,24)19(23)17(14)18/h11-12,19,22-24H,5-10H2,1-4H3/t19-,21-/m0/s1; Key:ZLYNXDIDWUWASO-FPOVZHCZSA-N;

Cannabitriol (CBT) is a phytocannabinoid first isolated in 1966, an oxidation product of tetrahydrocannabinol (THC) which has been identified both as a trace component of cannabis and as a metabolite in cannabis users. Its pharmacology has been little studied, though it has been found to act as an antiestrogen and aromatase inhibitor.